Stockreport

Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada

ACADIA Pharmaceuticals Inc.  (ACAD) 
Last acadia pharmaceuticals inc. earnings: 2/26 04:05 pm Check Earnings Report
PDF SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Health Canada has accepted its New Drug Submission (NDS) for trofinetide [Read more]